RELATED STUDY
Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study
Key Findings: Complete remission (Crohn's Disease Activity Index (CDAI) score, 100) was observed in 10 of 11 subjects in the cannabis group and 4 of 10 in the placebo group. Three patients in the cannabis group were weaned from steroid dependency. Subjects receiving cannabis reported improved appetite and sleep, with no significant side effects.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 21
Study Result: Positive
Research Location(s): Israel
Year of Pub: 2013
Cannabinoids Studied: Tetrahydrocannabinol (THC)
Phytocannabinoid Source: Cannabis Flower derived
Chemotype: Chemotype I
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Inhalation
Cannabinoid Ratio: (THC) 0 
Dosage Form: Each cigarette contained 0.5 g of dried cannabis flowers (flowers have a higher THC content than leaves), corresponding to 115 mg THC
Dosing Regimen: THC (115 mg) or placebo twice a day
Treatment Duration: 8 weeks
Clinical Relevance: A short course of THC-rich cannabis produced significant clinical, steroid-free benefits.
Citation: Naftali T, et al. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013; 11:1276-1280.e1. doi: 10.1016/j.cgh.2013.04.034
Authors: Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM
